
    
      The study will consist of a 30-day screening phase, a 12-week placebo-controlled
      dose-titration phase, and a 16-week placebo-controlled efficacy assessment phase (EAP).
      Participants who complete 28 weeks on study will continue into an open-label safety extension
      phase for 24 weeks of investigational cinacalcet treatment.
    
  